Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license
TCF7L2 · rs34872471
Stands on its own. Nothing else here links to this position yet — but the page above is the point: what the research found, what each genotype means, and where it came from, in language you can read. Links to conditions, drugs and the senses appear automatically if we write them.
Strength of the evidence
Its strongest genetic-study result is p = 10−528, with 70 associations in the GWAS Catalog.
4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.
What the study found
Who was studied 746 African American cases, 2,825 African American controls, 743 East Asian ancestry cases, 3,992 East Asian ancestry controls, 7,111 European ancestry cases, 49,688 European ancestry controls, 1,147 Latino cases, 5,352 Latino controls; replicated in 12,171 European ancestry cases, 56,862 European ancestry controls.
The effect Each copy of the C allele carried 1.31 times the odds of Type 2 diabetes (95% confidence interval 1.26-1.35); p = 6 × 10−53.
How common The C allele had a frequency of about 28% in the people studied.
Where it sits Chromosome 10, band 10q25.2 — in an intron of TCF7L2.
How common each version is
CT
C 2.9% · T 97.1%
C 2.5% · T 97.5%
C 2.8% · T 97.2%
C 4.7% · T 95.3%
C 4.2% · T 95.8%
C 29.1% · T 70.9%
C 24.2% · T 75.8%
C 29.6% · T 70.4%
By ancestry gnomAD
C 2.6% · T 97.4%
C 29.4% · T 70.6%
C 34.9% · T 65.1%
C 30.3% · T 69.7%
C 27.2% · T 72.8%
C 41.5% · T 58.5%
C 18.9% · T 81.1%
C 30.3% · T 69.7%
The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races.
2026-05-22 · Sinnott-Armstrong N, et al., Nature Communications 2026, PMID:42173832
Genetic variants affect diurnal glucose levels throughout the day
Circadian rhythms regulate glucose metabolism as well as sleep, but which genetic variants govern the timing of glucose had not been examined. Using the time of day each blood sample was taken, this study of about 420,000 UK Biobank participants — replicated in the Estonian Biobank, FinnGen, the VA Million Veteran Program and the MGB Biobank — shows that glucose levels are under diurnal genetic control. The two robust time-dependent signals are at MTNR1B, the melatonin receptor (rs10830963), and at CRY2, a core circadian clock gene (rs12419690). Sleep modulated glucose levels, the variants acted independently of sleep, they independently changed the risk of type 2 diabetes, and sleep medications including melatonin were associated with type 2 diabetes. Those two headline positions are not on this site yet; 21 other positions from the study are, among them rs560887 (G6PC2), rs34872471 (TCF7L2), rs3802177 (SLC30A8) and rs11708067 (ADCY5). PMID:42173832.
Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license
Type 2 diabetes (rs34872471). MyGeneLog™. https://www.mygenelog.com/variants/rs34872471